In-line with Actavis’ strategy to grow and expand its Specialty Brands business globally, the Company has a commercial presence in Canada and is strengthening its presence in Latin America with organizational and regulatory milestones.
In Canada, Actavis significantly bolstered its presence in the country with the acquisition of Warner Chilcott, gaining seven approved product franchises, including Asacol®, Actonel® and Femhrt®. This follows Actavis’ recent launch in July 2013 of Fibristal™, the first medication in Canada approved for the treatment of uterine fibroids.
In 2012, Actavis further expanded its portfolio in Canada with the launch of Rapaflo® and Gelnique®, re-launched Androderm® and Oxytrol® and deployed a national sales force to drive growth.
In Latin America, Actavis Specialty Brands has made significant progress in advancing products expected to serve as the springboard for our Specialty Brands business in the region.
In 2012, Actavis filed regulatory submissions with ANVISA in Brazil for approval of Rapaflo®, which was received in mid-2013 and Gelnique®. We are also preparing to file Androderm® for approval in Brazil and Rapaflo® and Gelnique® for approval in Mexico.